A Phase 1/2A Trial of ENB 003 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Latest Information Update: 27 Sep 2024
At a glance
- Drugs ENB 003 (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Fallopian tube cancer; Head and neck cancer; Lipoma; Male breast cancer; Malignant melanoma; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Sarcoma; Soft tissue sarcoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms ENBolden; ENBOLDEN-101
- Sponsors ENB Therapeutics
Most Recent Events
- 07 Nov 2023 According to an ENB Therapeutics media release, the company is expected to start phase 2 of this study in first half of 2024.The trial will enroll MSS primary PROC, as well as MSS pancreatic cancer patients and patients with other advanced solid tumors that have failed standard of care.
- 07 Nov 2023 According to an ENB Therapeutics media release, data from this study was presented on November 3, 2023 at a poster session at the SITC 2023 meeting, was held November 1-5, in San Diego, California, USA.
- 07 Nov 2023 Results published in the ENB Therapeutics Media Release.